Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

mational," said Novavax Chief Executive Officer, Dr. Rahul Singhvi. "We eliminated 100% of our $22 million outstanding convertible debt and raised net proceeds of $21.9 million through the sale of additional shares under our ATM program. Today, Novavax has a healthy balance sheet with no long term debt and cash and short-term investments of $37.6 million as of July 31, 2009. With this financial strength, we are well positioned to advance our vaccine development programs, and in particular, continue our work on a VLP vaccine candidate against the 2009 pandemic H1N1 strain, so that we are ready to serve public health authorities in the U.S. as well as in foreign countries."

The anticipated milestones for the remainder of 2009 include:

  • Release top-line results from the Phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Initiate a Phase II clinical study of our trivalent seasonal flu vaccine in older adults;
  • Continue development of our pandemic H1N1 vaccine candidate;
  • Complete definitive license and supply agreements with ROVI; and
  • Continue expansion of operations at CPL Biologicals.

2009 Financial Results

Revenue from continuing operations for the second quarter ended June 30, 2009 was $29,000, compared to $0.3 million for the same period in 2008, a decrease of $0.3 million due to the completion of two contracts in 2009.

Research and development costs were $5.3 million for the second quarter of 2009 compared to $5.4 million in the second quarter of 2008, a decrease of $0.1 million. The decrease was due to a $0.2 million decrease in employee costs, partially offset by a $0.1 million increase in outside testing costs associated with continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... NextCODE Health, which enables clinicians and researchers to ... today announced the launch of its new genomic data analysis ... American Society of Human Genetics (ASHG) annual meeting in ... and apply for free beta access, visit www.nextcode.com . ... be viewed here . The Exchange: ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and segments ... revenue. The Automatic patient billing market in Asia is ... at a developing CAGR of 7.2% from 2013 to ... Automatic patient billing market, to get an idea of ... of the segmentation of this market in the same ...
(Date:10/19/2014)... 19, 2014 The report "Chocolate, Cocoa ... Trade, Prices, Geography Trend and Forecast (2011 - 2016)," ... and geography and studies the major market drivers, restraints, ... Europe, and Asia. , The global chocolate market is ... billion in 2016 at an estimated CAGR of 2.7% ...
(Date:10/19/2014)... The report "Unmanned Ground Vehicle Market by Application ... & by Geography - Forecasts & Analysis 2014–2020", ... market into various sub segments with an in-depth ... also identifies the factors driving this market, various ... adoption trends. , The unmanned ground vehicle market ...
Breaking Biology Technology:The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5
... 5 Schering-Plough Corporation (NYSE: SGP ) ... by David Nicholson, Ph.D., senior vice president, Global Project ... Barclays Capital Global Healthcare Conference in Miami on Tuesday, ... is expected to talk about the company,s R&D pipeline ...
... rosacea-specific study also slated for presentation at American Academy ... NAPA, Calif., March 5 Senetek PLC (OTC Bulletin ... development of technologies that target the science of healthy ... at the American Academy of Dermatology,s 67th Annual Meeting ...
... SAN FRANCISCO, Calif., March 5 Poniard Pharmaceuticals, ... company focused on innovative oncology therapies, today announced ... discuss the Company,s fourth quarter and year-end financial ... development activities for picoplatin, the Company,s lead product ...
Cached Biology Technology:Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 3Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12 2
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... PA, October 28, 2008 A growing body of ... from grapes, including red wine, helps reduce the risk ... the November issue of Nutrition Research . ... such as red wine may be beneficial in preventing ...
... However, how the step from gene to anti-bacterial effect occurs ... B. Pseudomallei, a bacterium suitable for bioweapons, had managed ... body for many years without being detected by the immune ... the body, resulting in the patient dying from blood poisoning. ...
... event organised by the trinational Transalpine Biocluster ... will bring together researchers and professionals from academia ... the most recent findings in the fields of ... new and exciting developments in the technology and ...
Cached Biology News:Mounting evidence shows health benefits of grape polyphenols 2Bridging public and private research on bioinformatics and proteomics 2